David A. Mankoff
Has grant
Matthew J Wilson Professor and Research Vice-Chair of Radiology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
ACC-PREP: Proposal for ACS DICR Post-Bac Program
Open Date: 2024-01-01
Close Date: 2026-12-31
Articles (29)
Year:
2026
The ternary complex of progesterone receptor membrane component 1 (PGRMC1)–sigma-2 receptor/transmembrane protein 97 (σ2R/TMEM97)–low-density lipoprotein receptor (LDLR) has recently been discovered and plays a role in cholesterol transport. This study investigated whether individual components of that complex are prognostic breast cancer biomarkers and have defined expression in established molecular subtypes. A total of 4,463 invasive breast cancers were analyzed as a function of molecular and phenotypic markers, estimates of cellular proliferation, and recurrence-free survival. A gene expression signature–based assay was utilized to estimate cellular proliferation. Cox proportional hazards regression estimated relapse-free survival and multivariate Cox analysis adjusted for the association of proliferation with early relapse. PGRMC1–σ2R/TMEM97–LDLR expression was stratified by immunohistochemical (IHC) and molecular subtype, tumor grade, and size. TMEM97 exhibited the strongest correlation with proliferation, highest in estrogen receptor (ER)–positive disease (r = 0.59, P = 8.1−114). TMEM97 and PGRMC1 were associated with a risk of early recurrence, dependent upon their association with proliferation. The risk of early recurrence was highest with TMEM97 and only seen in ER+/HER2− disease [HR = 1.5; 95% confidence interval (CI) = 1.35–1.67; P = 5.4−14] and ER+ malignancies (HR = 1.49; 95% CI = 1.31–1.68; P = 3.1−10). There was no increased risk of recurrence with TMEM97 expression in ER−/HER2− (HR = 1.05; 95% CI = 0.88–1.25; P = 0.63) or ER− disease (HR = 1.02; 95% CI = 0.89–1.17; P = 0.75). Components of a ternary complex associated with rapid internalization of low-density lipoprotein are biomarkers associated with cellular proliferation and early recurrence, which should help guide studies exploring them in the context of additional markers of aggressive disease. Elucidating the role of PGRMC1, TMEM97, and LDLR in breast cancer will facilitate a mechanistic understanding of how proliferation interplays with cholesterol metabolism in malignant transformation or propagation. Significance: This first large-scale analysis of the putative ternary complex responsible for rapid low-density lipoprotein internalization in breast cancer reveals a link between component expression and recurrence, with prognostic implications for identifying patients needing supplemental posttreatment surveillance and/or additional therapeutic approaches.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Trimethoprim (TMP) is a reversible inhibitor of the prokaryotic enzyme dihydrofolate reductase (DHFR) used for the treatment or prophylaxis of bacterial infections. [ 11 C]trimethoprim ([ 11 C]TMP) is a positron emission tomography (PET) imaging isotopologue of TMP. TMP binds with 30,000-fold greater affinity to bacterial DHFR over the homologous mammalian enzyme in vitro , suggesting [ 11 C]TMP may selectively accumulate in tissues with cells expressing bacterial DHFR. This study characterizes the biodistribution and dosimetry of [ 11 C]TMP, informing its use in imaging bacterial infections and tracking mammalian cells expressing eDHFR as a reporter gene. Methods Four males with suspected infection, aged 59 ± 10 years old (mean ± SD) received 3 serial PET/CT scans after injection of 346 ± 305 MBq (range 129–797 MBq) of [ 11 C]TMP. Organ activities were measured in MIM v6.7, including brain, kidneys, spleen, liver, heart, lungs, bladder, intestines, gallbladder, pancreas, thyroid, and red marrow. Dosimetry calculations were performed in Olinda | EXM v1.1. Additionally, a dynamic whole-body PET/CT scan was performed on a separate participant. The associated trial was registered as NCT03424525. Results [ 11 C]TMP injections were well tolerated with no adverse events. The average injected activity of 346 MBq of [ 11 C]TMP yielded an estimated average dose of 4.9 mSv in the highest uptake organ (liver), 4.1 mSv in the spleen, and an effective dose of 1.6 mSv. Suspected sites of infection displayed uptake above background. Conclusion [ 11 C]TMP PET was safe and demonstrated low background uptake in most tissues. The data suggests feasibility for evaluation of varied bacterial infections, including musculoskeletal infections. Absorbed doses allow multiple [ 11 C]TMP PET scans each year within Radioactive Drug Research Committee (RDRC) limits, potentially enabling monitoring of infections and treatment response.
Year:
2025
Background 18 F-Fluorodeoxyglucose (FDG) and 18 F-Fluorestradiol (FES) have been FDA approved for measuring tumor glycolytic activity and estrogen receptor (ER) uptake, respectively, in clinical positron emission tomography (PET) imaging for patients with hormone-receptor (HR) positive metastatic breast cancer (MBC), but little is known about its utility in patients with breast tumors that overexpress human epidermal growth factor 2 (HER2). We hypothesize that comparing patterns of FDG and FES uptake in patients with HER2-positive versus HER2-negative MBC can guide further biologic and clinical studies into the HR/HER2-positive phenotype. Methods We conducted a retrospective study examining uptake in matched lesions for FES and FDG-PET scans, assessing these parameters in 213 patients with ER-positive/HER2-positive ( n = 33) versus ER-positive/HER2-negative MBC ( n = 180). We employed log-rank and t-tests to assess the association of HER2 status with outcome variables and the hypotheses that patients expressing HER2-positive disease lived longer than patient with HER2-negative disease. Results No difference in FES or FDG avidity was observed between patients with HER2-negative or HER2-positive tumor status. Limited data also suggests that patients with HER2-positive disease had better overall survival ( p = 0.024), than those with HER2-negative disease, but not time-to-progression between the same patient cohorts. Conclusion This retrospective analysis suggests that there is a possible role for future trials using FES-PET in helping to select patients with ER+/HER2-positive primary tumors who retain ER expression at all sites of disease and may benefit from endocrine therapy.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2023
Collaborators (23)
Fenghai Duan
Professor
Brown University
Mark A. Sellmyer
University of Pennsylvania
Gordon Mills
Professor
Oregon Health & Science University
Christopher Hensley
Assistant Professor in Molecular Imaging and Therapeutics
University of Alabama, Tuscaloosa
Lainie Martin
University of Pennsylvania Perelman School of Medicine
Jennifer Holter Chakrabarty
Associate Professor
University of Oklahoma College of Medicine
Robert Mach
Britton Chance Professor
University of Pennsylvania
Fiona Simpkins
-
Lilie L. Lin
Associate Professor
The University of Texas MD Anderson Cancer Center
Ramsey Badawi
Professor
university of california davis medical center
Jennifer Specht
Professor
Fred Hutchinson Cancer Research Center
Janos Tanyi
Assistant Professor
University of Pennsylvania
Melissa A. Troester
Professor
University of North Carolina at Chapel Hill
Philipose Mulugeta
Associate Professor of Radiology
University of Pennsylvania
Daniel Arber
Professor and Chair
University of Chicago
Stephen Strickland
Assistant Professor of Medicine
Vanderbilt University Medical Center
Drew Torigian
Professor, Clinician-Educator
University of Pennsylvania
Andrew Kossenkov
Assistant Professor
The Wistar Institute
JEREMIE CALAIS
Professor
David Geffen School of Medicine at UCLA
Lewis Chodosh
Professor and Chairman
University of Pennsylvania
Robert Jeraj
Professor
University of Wisconsin-Madison
Elizabeth McDonald
University of Pennsylvania
Sarah Gitto
Assistant Research Professor
University of Pennsylvania
Make your next move.
Prepare your application
Review drafts before you send them.